Boston Trust Walden Corp Sells 59,127 Shares of CorVel Corp. $CRVL

Boston Trust Walden Corp lessened its holdings in CorVel Corp. (NASDAQ:CRVL) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 435,025 shares of the business services provider’s stock after selling 59,127 shares during the quarter. Boston Trust Walden Corp’s holdings in CorVel were worth $23,774,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of CorVel during the 3rd quarter worth $31,000. Los Angeles Capital Management LLC bought a new stake in shares of CorVel during the 4th quarter worth $33,000. Quarry LP raised its stake in CorVel by 218.6% during the third quarter. Quarry LP now owns 513 shares of the business services provider’s stock worth $40,000 after acquiring an additional 352 shares in the last quarter. Eagle Bay Advisors LLC acquired a new position in CorVel during the fourth quarter worth about $37,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of CorVel by 66.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider’s stock worth $39,000 after acquiring an additional 230 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

CorVel Stock Performance

Shares of CRVL opened at $64.14 on Friday. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of 29.97 and a beta of 0.98. The stock has a 50 day moving average of $59.79 and a 200 day moving average of $59.19. CorVel Corp. has a 12 month low of $44.83 and a 12 month high of $103.06.

CorVel (NASDAQ:CRVL) last posted its quarterly earnings results on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. The company had revenue of $248.55 million during the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.

Insider Activity

In related news, VP Jennifer Yoss sold 1,999 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $61.02, for a total transaction of $121,978.98. Following the completion of the transaction, the vice president directly owned 2,173 shares in the company, valued at $132,596.46. The trade was a 47.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Maxim Shishin sold 2,250 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $60.59, for a total value of $136,327.50. Following the completion of the sale, the insider directly owned 7,050 shares of the company’s stock, valued at approximately $427,159.50. This represents a 24.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 13,249 shares of company stock worth $807,126. 44.56% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CRVL has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of CorVel from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Weiss Ratings downgraded shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).